Simulations Plus to Participate in Upcoming Investor Conferences

Simulations Plus, Inc. (Nasdaq: SLP), a distinguished provider of cheminformatics and biosimulation solutions, has announced its participation in key investor conferences scheduled for September 2025. CEO Shawn O’Connor will engage with investors during these pivotal events, which aim to showcase the company’s innovative contributions to the biopharma industry.

The first event is the 2025 Wells Fargo Healthcare Conference, taking place in Boston, Massachusetts, on September 3-4, 2025. This conference is structured around a fireside chat format complemented by one-on-one meetings, providing an intimate setting for discussions about Simulations Plus' technological advancements and market strategies. O’Connor is slated to present on September 3 at 12:45 PM ET, with a webcast available for those unable to attend in person.

Following this, Simulations Plus will participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference in New York City on September 10, 2025. Similar to the Wells Fargo conference, this event will also feature a fireside chat and opportunities for one-on-one meetings. The live presentation is scheduled for 2:35 PM ET on the same day.

With over 25 years of experience, Simulations Plus has established itself as a leader in providing cutting-edge software and consulting services that support drug discovery, development, and commercialization. The company's solutions harness the power of artificial intelligence and advanced modeling techniques, making them indispensable to pharmaceutical and biotechnology enterprises as well as regulatory agencies globally.

For additional details on registration or inquiries about the events, interested parties are encouraged to contact their representatives at Wells Fargo and Morgan Stanley. To stay updated, individuals can visit Simulations Plus' website or follow them on LinkedIn, X, and YouTube.

Simulations Plus, Inc. (Nasdaq: SLP) is strategically positioning itself for significant visibility in the biopharma sector by participating in two upcoming investor conferences: the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. These events, scheduled for September 3-4 and September 10, 2025, respectively, will feature CEO Shawn O’Connor in fireside chats and one-on-one meetings, highlighting the company’s innovative contributions to drug discovery and development.

Investors should view these conferences as pivotal opportunities for Simulations Plus to articulate its growth narrative, particularly in the context of its advanced biosimulation solutions. With its comprehensive suite of services incorporating cutting-edge AI and machine learning technology, Simulations Plus remains at the forefront of biopharma innovation, an increasingly crucial area as the industry evolves.

From a financial perspective, participation in these high-profile events could bolster investor confidence and potentially drive stock performance. Firms with a solid track record and growth potential in the biopharmaceutical sector often see a favorable stock response to heightened market visibility and stakeholder engagement—especially when accompanied by positive performance indicators and market conditions.

Moreover, as Simulations Plus continues to expand its client base among leading pharmaceutical and biotechnology companies globally, the company stands to benefit from increased demand for its simulation-enabled performance and intelligence solutions. The forthcoming conferences could serve to reinforce key partnerships and catalyze new business opportunities.

As such, analysts and investors should consider monitoring developments around these conferences closely. Investing in Simulations Plus may offer attractive upside potential, especially if the company effectively communicates its strategic vision and growth trajectory during these events. Adopting a bullish stance ahead of these conferences could position investors favorably to capitalize on any resulting market momentum.